

INTROGEN THERAPEUTICS INC

Form 8-K

May 11, 2004

**Table of Contents**

---

---

**SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): May 11, 2004

**Introgen Therapeutics, Inc.**

---

(Exact name of registrant as specified in its charter)

Delaware

0-21291

74-2704230

---

(State or other jurisdiction  
of incorporation)

(Commission  
File Number)

(IRS Employer  
Identification No.)

301 Congress Avenue, Suite 1850, Austin, Texas

78701

---

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code: (512) 708-9310

---

(Former name or former address, if changed since last report)

---

---

---

**TABLE OF CONTENTS**

Item 7. Financial Statements and Exhibits.

Item 12. Results of Operations and Financial Condition.

SIGNATURES

INDEX TO EXHIBITS

Press Release

---

**Table of Contents**

**Item 7. Financial Statements and Exhibits.**

(c) Exhibits.

99.1 Press Release dated May 11, 2004.

**Item 12. Results of Operations and Financial Condition.**

On May 11, 2004, Introgen Therapeutics, Inc. issued a press release announcing financial results for the quarter ended March 31, 2004. A copy of this press release is attached hereto as Exhibit 99.1.

The information in this Current Report on Form 8-K is being furnished and shall not be deemed filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: May 11, 2004

INTROGEN THERAPEUTICS, INC.

/s/ James W. Albrecht, Jr.  
James W. Albrecht, Jr.  
Chief Financial Officer

-2-

---

**Table of Contents**

INDEX TO EXHIBITS

<b>Exhibit Number</b>	<b>Description of Document</b>
99.1	Press Release dated May 11, 2004.